Indications -- Hepatitis Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Hepatitis

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: russet who wrote (45)	7/14/2003 12:46:53 PM
From: keokalani'nui	of 312

[HepC. GenMab Inlicense. E2 envelope glycoprotein.] Genmab Expands Pipeline with Hepatitis Antibody Monday July 14, 7:01 am ET Rights Acquired to Human Antibody from Connex and INSERM Summary: Genmab acquires the rights to a human antibody from the administrators of Connex GmbH and from INSERM, to potentially treat Hepatitis C. COPENHAGEN, Denmark, July 14 /PRNewswire-FirstCall/ -- Genmab A/S (CSE: GEN - News) announced today that it had in-licensed all rights to a human antibody from Connex GmbH, a privately owned German company currently in administration, and INSERM, the French National Institute for Health and Medical Research. The antibody targets the E2 envelope glycoprotein on Hepatitis C virus and is intended to be used in the prevention and treatment of Hepatitis C virus infection.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next